HomeCompareSNCAF vs ABBV

SNCAF vs ABBV: Dividend Comparison 2026

SNCAF yields 0.09% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.5K in total portfolio value
10 years
SNCAF
SNCAF
● Live price
0.09%
Share price
$63.76
Annual div
$0.06
5Y div CAGR
-0.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.8K
Annual income
$9.03
Full SNCAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SNCAF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNCAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNCAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNCAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNCAF
Annual income on $10K today (after 15% tax)
$7.70/yr
After 10yr DRIP, annual income (after tax)
$7.68/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,048.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNCAF + ABBV for your $10,000?

SNCAF: 50%ABBV: 50%
100% ABBV50/50100% SNCAF
Portfolio after 10yr
$61.1K
Annual income
$12,390.39/yr
Blended yield
20.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SNCAF
Analyst Ratings
7
Buy
Consensus: Buy
Altman Z
3.4
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNCAF buys
0
ABBV buys
0
No recent congressional trades found for SNCAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNCAFABBV
Forward yield0.09%3.06%
Annual dividend / share$0.06$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-0.1%40.6%
Portfolio after 10y$19.8K$102.3K
Annual income after 10y$9.03$24,771.77
Total dividends collected$90.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: SNCAF vs ABBV ($10,000, DRIP)

YearSNCAF PortfolioSNCAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,709$9.05$11,550$430.00$841.00ABBV
2$11,468$9.05$13,472$627.96$2.0KABBV
3$12,280$9.05$15,906$926.08$3.6KABBV
4$13,148$9.05$19,071$1,382.55$5.9KABBV
5$14,078$9.05$23,302$2,095.81$9.2KABBV
6$15,072$9.04$29,150$3,237.93$14.1KABBV
7$16,136$9.04$37,536$5,121.41$21.4KABBV
8$17,275$9.03$50,079$8,338.38$32.8KABBV
9$18,493$9.03$69,753$14,065.80$51.3KABBV
10$19,796$9.03$102,337$24,771.77$82.5KABBV

SNCAF vs ABBV: Complete Analysis 2026

SNCAFStock

SNC-Lavalin Group Inc. operates as an integrated professional services and project management company. It operates through Engineering, Design, and Project Management (EDPM); Nuclear; Infrastructure Services; Resources; Infrastructure EPC (Engineering, Procurement, and Construction) Projects; and Capital segments. The EDPM segment provides consultancy, engineering, design, and project management services for the transportation, civil infrastructure, aerospace, defense and security, and technology sectors. The Nuclear segment supports clients across the nuclear life cycle with the spectrum of services, such as consultancy, field, technology, reactor support and decommissioning, and waste management services, as well as EPC management services. This segment also offers new-build and full refurbishment services for reactors; and spare parts. The Infrastructure Services segment undertakes operations and maintenance projects; and provides EPC services for district cooling plants and power substations. This segment also offers engineering solutions for the hydro, transmission and distribution, renewables, energy storage, and intelligent networks and cybersecurity sectors. The Resources segment provides project development, delivery, and support services primarily to the mining and metallurgy sector, as well as Build-Own-Operate contract services. The Infrastructure EPC Projects segment undertakes construction contracts for the mass transit, heavy rail, roads, bridges, airports, ports and harbors, and water infrastructure sectors. The Capital segment invests in infrastructure concessions, such as bridges and highways, mass transit systems, power facilities, energy infrastructure, water treatment plants, and social infrastructure. It has operations in the Asia Pacific, the United Kingdom, Europe, the Middle East, and the Americas. SNC-Lavalin Group Inc. was founded in 1911 and is headquartered in Montreal, Canada.

Full SNCAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SNCAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNCAF vs SCHDSNCAF vs JEPISNCAF vs OSNCAF vs KOSNCAF vs MAINSNCAF vs JNJSNCAF vs MRKSNCAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.